Gastrointestinal MicrobiomeNCT06564285
The Effects of a Novel Nutritional Product on Nutrient Gaps and Gut Health in Adults With Occasional Gastrointestinal Issues
A study testing AG1 - Nutritional Supplement in people with Gastrointestinal Microbiome and Nutrition, Healthy, run by Athletic Greens International at 1 site in United States.
Trial summary
This study is a randomized, double-blind, placebo-controlled study of N=40 adult men and women with occasional GI issues. This study to assess the effect of a novel dietary supplement on the gut microbiome, nutrient gaps, and tolerability. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Gastrointestinal Microbiome, Nutrition, Healthy
- What is being tested?
- AG1 - Nutritional Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Aug 2024to 1 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
To be eligible to participate in this study, an individual must meet all of the following criteria:
- Provide voluntary signed and dated informed consent.
- Does not have any chronic health conditions that could impact participation in this study such as oncological or psychiatric disorders.
- No known history of chronic illness or disease.
- Aged between 18 and 60 years (inclusive).
- Body Mass Index of 20-34.9 (inclusive).
- Agree to maintain existing dietary and physical activity patterns throughout the study period.
- Willing and able to comply with the study protocol.
- Self-reported gastrointestinal symptoms, such as self-reported abdominal pain, gas and bloating after meals, heartburn/acid reflux after meals, and issues with digestion.
- Must be in good general health.
- Following a stable, consistent diet pattern.
- Agree to refrain from any lifestyle changes that may affect their GI tract and IBS symptoms for the duration of the study.
- Not currently taking and not planning on introducing any product, supplement or medication aimed at gut health or nutritional gaps during the study period.
- Resides in the United States.
An individual who meets the following criteria will be excluded from participation in this study:
- Prior prescriptions for IBS or any other medication (OTC and prescription) targeting the gut.
- Taking any supplements targeting the gut in the past 30 days.
- Current IBS treatment (e.g. proton pump inhibitors, laxatives).
- Follow an extreme diet intervention. This includes specific exclusion-type diets like vegan, vegetarian, carnivore, paleo, Atkins, ketogenic etc.
- Experienced significant weight loss (10% total body weight) in the past 3 months prior to study participation.
- Usage of any medication or herbal remedies which can affect the GI tract.
- Food intolerances/allergies.
- History of GI tract cancers.
- Celiac disease/gluten intolerance.
- Pregnant women, women trying to conceive, women less than 120 days postpartum, or nursing women.
- Anyone with any allergy requiring the use of an Epi-pen.
- Multivitamin/Multimineral supplement consumption within the past 3 months.
- History of use of medications or dietary supplements known to confound the study or its endpoints.
- History of unstable or new-onset cardiovascular, liver, or renal conditions.
- History of diabetes or endocrine disorder.
- Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 90 days prior to the study.
- Excessive alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) within the past 6 months.
- Current smokers or smoking within the past month.
- History of drug abuse or dependence.
- History of hyperparathyroidism or an untreated thyroid condition.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- Prior gastrointestinal bypass surgery (Lapband, etc.).
- Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, IBS/IBD, diarrheal illnesses, history of colon resection, gastroparesis, and Inborn errors of metabolism (such as PKU).
- Diagnosed chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
- Previous medical diagnosis of asthma, gout, or fibromyalgia.
- A change in hormone therapy, including oral contraceptives, within 4 weeks prior to screening, or unwilling to maintain current hormone therapy/oral contraceptive use throughout the course of the study.
- Known allergy or sensitivity to any ingredient in the test formulations as listed in the product label or in the placebo ingredients.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days or planning on taking part in another research study during this study's duration.
- Has undergone any surgery or invasive treatments in the previous six months or has any planned for during the study period.
- Anyone taking any supplements that have the same ingredients as those in the test product.
- Has taken a probiotic, prebiotic, or postbiotic in the past 30 days.
- Currently taking any opioid medications such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, or kratom.
Trial locations and contacts
1 site in 1 country.
About this study
This study is a randomized, double-blind, placebo-controlled study of N=40 adult men and women with occasional GI issues. This study to assess the effect of a novel dietary supplement on the gut microbiome, nutrient gaps, and tolerability.
- Conditions
- Gastrointestinal Microbiome, Nutrition, Healthy
- Being tested
- AG1 - Nutritional Supplement, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AG1 - Nutritional SupplementDietary supplement
A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
PlaceboDietary supplement
Maltodextrin placebo
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Maltodextrin + Flavoring Receives: Dietary Supplement: Placebo |
| AG1 - Nutritional Supplement | Experimental | A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients Receives: Dietary Supplement: AG1 - Nutritional Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut Microbiome
Examine changes in the gut microbiome via fecal metagenomics and metabolomics
Measured: 14 days
Secondary outcomes (1)
Nutrient Gaps
Assess nutrient gaps by dietary record assessment utilizing The Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2024
- Study start28 Aug 2024
- Primary completion1 Feb 2025
- Study completion1 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastrointestinal MicrobiomeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, Double-Blind, Placebo Controlled Design
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Athletic Greens International
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06564285
- Sponsor's protocol ID
- AG-AG1-53-09
- Status last verified
- May 2025
- First submitted
- 19 Aug 2024
- Last updated
- 4 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of a Novel Nutritional Product on Nutrient Gaps and Gut Health in Adults With Occasional Gastrointestinal Issues
- ClinicalTrials.gov ID
- NCT06564285
- Acronym / sponsor ID
- AG-AG1-53-09
- Conditions
- Gastrointestinal Microbiome, Nutrition, Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Athletic Greens InternationalIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2024 (actual)
- Primary completion
- 1 Feb 2025 (actual)
- Study completion
- 1 Feb 2025 (actual)
- First posted
- 21 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized, double-blind, placebo-controlled study of N=40 adult men and women with occasional GI issues. This study to assess the effect of a novel dietary supplement on the gut microbiome, nutrient gaps, and tolerability.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized, Double-Blind, Placebo Controlled Design
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: PlaceboMaltodextrin + Flavoring |
| AG1 - Nutritional Supplement | Experimental | Dietary Supplement: AG1 - Nutritional SupplementA foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AG1 - Nutritional SupplementA foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients | Dietary supplement | AG1 - Nutritional Supplement |
| PlaceboMaltodextrin placebo | Dietary supplement | Placebo |
Primary outcome
Gut Microbiome
Time frame: 14 days
Examine changes in the gut microbiome via fecal metagenomics and metabolomics
1 secondary outcome
Nutrient Gaps
Time frame: 14 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2025.
- Individual participant dataSharing planned: No
Related trials for Gastrointestinal Microbiome
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Active, not recruiting
SweetSpot - The Effect of Non-nutritive Sweeteners on Health
Healthy Adult
Enrolling by invitation
Dance-Based Exercise for Cancer-Related Fatigue in Breast Cancer Patients
Breast Neoplasms
Recruiting
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals
Gastrointestinal Microbiome (Focus), Gastrointestinal Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AG1 - Nutritional Supplement in people with Gastrointestinal Microbiome and Nutrition, Healthy, run by Athletic Greens International at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut Microbiome (time frame: 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2025.